What is it about?
This review gives a summary of current knowledge and future perspectives on GLP-1 and its analogues that are used in type 2 diabetes therapy. This review highlights recent evidence which suggests that GLP-1 and its analogues may have therapeutic applications beyond just augmenting glucose-stimulated insulin secretion from pancreatic islet beta-cells, which has high clinical relevance given the prevalence of post-diagnosis complications associated with T2D.
Featured Image
Why is it important?
Given that post-diagnosis complications of type 2 diabetes are common despite the treatment regimes that are available, a new more effective treatment option for T2D is highly desirable, which is able to further alleviate the systemic pathology associated with this disease.
Perspectives
Emerging evidence suggests that GLP-1 and it analogues used in T2D therapy have important homeostatic actions beyond just augmenting glucose-stimulated insulin secretion, which has high clinical relevance given the prevalence of post-diagnosis complications of T2D. Future GLP-1 based therapies can be designed to build on these findings which may provide more effective treatments for T2D, by alleviating the systemic pathology associated with this disease to a greater extent than current therapies.
Joshua reed
Swansea University
Read the Original
This page is a summary of: Recent advances in understanding the role of glucagon-like peptide 1, F1000Research, April 2020, Faculty of 1000, Ltd.,
DOI: 10.12688/f1000research.20602.1.
You can read the full text:
Contributors
The following have contributed to this page
